Gary A. Gelbfish, M.D., as Non-executive Chairman, has been a director of CorMedix since December 2009. He has been in private practice as a Vascular Surgeon since 1990. Dr. Gelbfish has practiced vascular surgery at Beth Israel Hospital since 1990 and has practiced vascular surgery at New York University Downtown Hospital since 2003. Since 1997, Dr. Gelbfish has served as an Assistant Clinical Professor of Surgery at Mt. Sinai Hospital. Dr. Gelbfish received a B.S. from Brooklyn College, holds an M.D. from Columbia University and completed his fellowship in vascular surgery at Maimonides Medical Center.
Antony E. Pfaffle, M.D., as Vice Chairman, has been a director of CorMedix since February 2007. Dr. Pfaffle is the Advisory Chief Medical Officer at ParagonRx, an Inventiv Health Company. He has been the Director of Healthcare Research at Bearing Circle Capital, L.P., an investment fund, since May 2007. He was a Managing Director at Paramount BioCapital, Inc. and Senior Vice-President of Business Development at Paramount BioSciences, LLC from December 2005 to May 2007. Dr. Pfaffle was a Principal and Founder of Black Diamond Research, an investment research company, from July 2001 to December 2005. Dr. Pfaffle is an internist who practiced nephrology at New York Hospital, Lenox Hill and Memorial Sloan-Kettering. Dr. Pfaffle received his M.D. degree from New York Medical College in 1989.
Steven W. Lefkowitz has been a director of CorMedix since August 2011. Since 1990, he has been the President and Founder of Wade Capital Corporation which focuses on small to middle market firms as it relates to setting strategy, developing business plans, raising capital, and identifying and executing business development transactions. Mr. Lefkowitz currently holds Board positions in both publicly traded and privately held companies. Mr. Lefkowitz holds an M.B.A. in finance from Columbia University Graduate School of Business.
Matthew P. Duffy has been a director of CorMedix since November 2011. Since 2001, Mr. Duffy has been a managing partner of Black Diamond Research (BDR), LLC. Mr. Duffy is a founder of Algorithm Sciences, LLC and Identic Pharmaceuticals, both start-up bio-pharmaceutical companies. In 2007 and 2008, Mr. Duffy led commercial operations at Lev Pharmaceuticals, overseeing launch preparations for Cinrzye, an Orphan Drug for hereditary angioedema, including forming the sales team, developing the marketing plan, distribution plan, managed care strategy and patient services infrastructure. Currently Cinryze has annualized sales over $250 million. Prior to founding BDR, Mr. Duffy led the Marketing group at MedImmune, Inc. from 1995 to 2001, where he was responsible for the launch of both RespiGam and Synagis for the prevention of respiratory disease in premature infants, as well as new indications for CytoGam in the transplantation field. Synagis sales have exceeded $1 billion. In addition to working on various product launch efforts, Mr. Duffy also was responsible for market and product evaluations for MedImmune's development pipeline, as well as the company's customer service call center. Mr. Duffy began his career at Pfizer, Inc. holding a series of line and executive positions in sales, and marketing/product management. At Pfizer, he worked on over 10 different pharmaceutical products, including treatments for depression, diabetes, infectious diseases, urologic disorders and hypertension. Mr. Duffy was the first product manager for Viagra®. Mr. Duffy received his undergraduate degree from Duke University. He holds the series 7, 63 and 65 securities licenses. Mr. Duffy also served as the Treasurer of Ridgefield Academy an Independent School in Ridgefield, CT, and is a member of the Board of Trustees. Mr. Duffy is also a managing member of NSIP LLC; member, and member of the Executive Committee of Ellington Asset Management LLC, a healthcare focused venture capital fund.
Randy D. Milby is an established leader with executive accomplishments in the global pharmaceutical, medical device, agricultural and bio-polymer industries. He has led commercial operations for several businesses including profit/loss responsibility, product development functions, international product launches, domestic and international negotiations to develop partnerships, and financial management. Mr. Milby began his career in the pharmaceutical industry assessing markets and shepherding compounds from research through launch. Then he transitioned from launching products to launching businesses. He utilizes market research to gain an understanding of new markets and provides necessary leadership to highly productive teams working on complex projects. During his career he has worked at Bristol-Myers Squibb, DuPont Merck Pharmaceuticals, Goldman Sachs and DuPont. Mr. Milby received his B.S from the Kansas School of Pharmacy and earned his Master of Business Administration with an emphasis in marketing and finance from Washington University in St. Louis.